Loading...

Accelerate Diagnostics, Inc.

0H8E.LLSE
Healthcare
Medical - Specialties
£0.01
£0.00(0.80%)

Accelerate Diagnostics, Inc. (0H8E.L) Stock Overview

Explore Accelerate Diagnostics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B+

Score: 70.3/100

Key Financials

Market Cap138.7K
P/E Ratio-0.01
EPS (TTM)$-1.06
ROE1.21%
Fundamental Analysis

AI Price Forecasts

1 WeekN/A
1 Month$0.02
3 Months$0.58
1 Year Target$1.53

0H8E.L Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Accelerate Diagnostics, Inc. (0H8E.L) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 0.58, suggesting the stock is in an oversold condition. Our forecasting models predict significant price movements, with a 12-month target of $1.53.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.01 and a market capitalization of 138.7K. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

0.58RSI (14)
-0.15MACD
85.92ADX
Revenue Growth
-2.99%
2.99%
Profit Growth
£-1.99
18.78%
EPS Growth
£-1.99
56.48%
Operating Margin
-301.86%
34.64%
ROE
121.19%
18.78%
Dividend Yield
0.00%
Analyst Recommendations data is not available for 0H8E.LAnalyst Recommendations details for 0H8E.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.

CEO

Jack Phillips

Employees

107

Headquarters

3950 South Country Club Road, Tucson, AZ

Founded

2018

Frequently Asked Questions

;